Information and decision-making preferences of hospitalized adult cancer patients

Blanchard, Christina G.; Labrecque, Mark S.; Ruckdeschel, John C.; Blanchard, Edward B.

doi:10.1016/0277-9536(88)90343-7

Cited by 448 publications

(280 citation statements)

References 15 publications

Supporting

Mentioning

252

Contrasting

Unclassified

Order By: Relevance

“…Another may be that the patients' ability to comprehend and the desire to obtain information was truly underestimated. The latter explanation is in accordance with the finding by others suggesting that physicians have difficulties in estimating the amount and type of information that patients want and their effectiveness in imparting information (Blanchard et al, 1988;Mackillop et al, 1988;Wiggers et al, 1990).…”

Section: Resultssupporting

confidence: 91%

Patient–physician communication concerning participation in cancer chemotherapy trials

2004

View full text Add to dashboard Cite

Cancer patients demand a high level of involvement in decisions concerning treatment. Many patients are informed about experimental trials, and especially the first consultation may be crucial for the future communication and treatment process. Patients with nonresectable non-small-cell lung cancer or colorectal cancer informed about experimental chemotherapy completed a questionnaire on satisfaction with the communication process, general attitude towards experimental treatments, the substance of information, and personal contact with the physician following their first consultation in a medical oncology unit. Physicians completed a questionnaire on their perception of the patients' satisfaction. Among 68 physician -cancer patient pairs, 29 patients were informed on chemotherapy in randomised trials and 39 in nonrandomised studies. The general attitude towards experimental treatment was positive or very positive in 71% of patients. Information on the treatment was perceived as completely adequate in 93% of patients informed on randomised and in 67% informed on nonrandomised trials. Physicians underestimated the patients' satisfaction with the overall communication process, the personal contact, the patients' perceived sufficiency of the specific treatment information and their ability to decide on study entry. In conclusion, considerable differences were observed between patients informed about experimental chemotherapy in randomised and nonrandomised trials, both with respect to their perception of how adequate the information on the specific treatments were, and whether it was sufficient for decisions on study entry. This study type effect should be accounted for in future evaluations of communication and patient satisfaction. The data also support the fact that cancer patients have a desire for and ability to understand rather detailed and comprehensive treatment information.

show abstract

Section: Resultssupporting

confidence: 91%

Patient–physician communication concerning participation in cancer chemotherapy trials

2004

View full text Add to dashboard Cite

show abstract

“…Research has shown, however, that while patients typically express high preferences for information about their illness and its treatment (Cassileth et al, 1980;Strull et al, 1984;Beisecker, 1988;Blanchard et al, 1988;Ende et al, 1989;Lerman et al, 1990;Beisecker and Beisecker, 1990;Waterworth and Luker. 1990;Silverstein et al, 1991;Biley, 1992;Deber, 1994), their preferences for participation in treatment decision-making are much more diversely distributed (Vertinsky et al, 1974;Strull et al, 1984;Pendleton and House, 1984;Ende et al, 1989;Beisecker and Beisecker, 1990;Silverstein et al, 1991;Degner and Sloan, 1992;Ryan, 1992;Hack et al, 1994).…”

Section: Models Of Treatment Decision-makingmentioning

confidence: 99%

Shared decision-making in the medical encounter: What does it mean? (or it takes at least two to tango)

Charles

Gafni

Whelan

1997

Social Science & Medicine

3,395

2,638

View full text Add to dashboard Cite

“…Some people fear that providing patients with such information may highlight for them the advanced nature of their disease and thereby induce a degree of anxiety and despair. However, a number of studies have showed that cancer patients generally wish to be involved in decisions that affect their treatment (Cassileth et al, 1980;Blanchard et al, 1988;Sutherland et al, 1989;Rothenbacher et al, 1997). In the study by Cassileth et al (1980) patients were asked about their preferences for r(ceiving information and participation in the decision-makin process.…”

Section: Patients' Preferences For Information and Participationmentioning

confidence: 99%

Assessing patients' needs and preferences in the management of advanced colorectal cancer

Redmond

1998

Br J Cancer

View full text Add to dashboard Cite

Summary Clinical decision-making in advanced cancer is a highly complex process. Many factors are thought to influence this processarguably the most important of these is the patient's own preference. Studies show that most patients want to be fully informed as to their diagnosis and involved in clinical decision-making. However, the attitudes of healthcare workers often preclude patient involvement. Studies have also shown that acceptability of chemotherapy for minimal therapeutic gain differs markedly between patients depending on factors such as age, gender and family status. It is clearly impossible to make decisions about what is best for patients without involving them in the decision-making process. Indeed, it could be argued that active patient participation actually simplifies this process.

show abstract

Information and decision-making preferences of hospitalized adult cancer patients

Cited by 448 publications

References 15 publications

Patient–physician communication concerning participation in cancer chemotherapy trials

Patient–physician communication concerning participation in cancer chemotherapy trials

Shared decision-making in the medical encounter: What does it mean? (or it takes at least two to tango)

Assessing patients' needs and preferences in the management of advanced colorectal cancer

Contact Info

Product

Resources

About